Kropeit Zhu, G. Nucci, R. S. Wallis; Pfizer Inc., Groton, C Flanagan, Minassian, E. Fang, K. Bartizal, P. Prokocimer; Trius Thera- peutics, San Diego, CA. Mega

300 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 161 A Poster Session Clinical Pharmacology of Antiviral and Anti-Tubercu- losis Agents Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1268a Long Half-Life is a Key Feature for High Potency of AIC316 against HSV-2

J. T. Schiffer

1 , A. Wald 1 , D. McCormick 2 , B. Timmler 2 , H. Rubsamen- Schaeff 2 , A. Birkmann 2 ; 1 Fred Hutchinson Cancer Res. Ctr., Seattle, WA, 2 Aicuris, Wuppertal, Germany. A-1268b First Single Intravenous Dose Escalation Data in Volun- teers for Letermovir: A Novel Anti-Human Cytomegalovirus Drug Entering Phase 3

D. Kropeit

1 , J. Scheuenpflug 1 , K. Erb-Zohar 2 , H. Stobernack 1 , D. McCormick 3 , M. Richard, MD - CMO 1 , H. Zimmermann 1 , H. Rübsamen-Schaeff 1 ; 1 AiCuris, Wuppertal, Germany, 2 Clinphase, Hanau, Germany, 3 DMPK Solutions Ltd., Nottingham, United Kingdom. A-1268c Investigation of the Effect of Oral Letermovir Administra- tion; A Novel Anti-Human Cytomegalovirus Drug Entering Phase 3, on the Pharmacokinetics of a Single Oral Dose of P-GP MDR1 Substrate Digoxin in Volunteers J. Scheuenpflug 1 , D. Kropeit 1 , K. Erb-Zohar 2 , J. G. W. Theis 3 , H. Stober- nack 1 , D. McCormick 4 , M. Richard 1 , H. Zimmermann 1 , H. Rübsamen- Schaeff 1 ; 1 AiCuris, Wuppertal, Germany, 2 Clinphase, Hanau, Germany, 3 InHeCon, Bergisch Gladbach, Germany, 4 DMPK Solutions Ltd, Notting- ham, United Kingdom. A-1268d The Blood Bactericidal Activity of PNU-100480 Sutezolid, U-480 and its Major Active Metabolite PNU-101603 U-603 in Patients with Pulmonary TB: Insight from PKPD Modeling T. Zhu, G. Nucci, R. S. Wallis; Pfizer Inc., Groton, CT. ------------------------------------------------------------------------ 163 A Poster Session PharmacokineticsPharmacodynamics of New and Old Oxazolidinones Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: A-1295a Lack of MAO Inhibition by Tedizolid Phosphate in Clinical and Nonclinical Studies S. Flanagan, S. Minassian, E. Fang, K. Bartizal, P. Prokocimer; Trius Thera- peutics, San Diego, CA. ------------------------------------------------------------------------ 164 B Poster Session Antimicrobial Therapy in Animal Models II Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: B-1308a Efficacy of Intravenous Plazomicin in the African Green Monkey AGM Inhalational Plague Model

W. Mega

1 , R. Cirz 2 , R. Cass 2 , N. Reyes 2 , M. Valderas 1 , R. Sherwood 1 ; 1 LRRI, Albuquerque, NM, 2 Achaogen, Inc., South San Francisco, CA. ------------------------------------------------------------------------ 165 B Poster Session Microbial Determinants of Virulence Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: B-1338a Development of Anthrax in a Macaque Model after Inges- tion of Bacillus anthracis Spores Z. Llewellyn 1 , N. Richardson-Harman 2 , J. Mann 1 , R. May 1 , B. Yamamoto 1 , J. Toomey 1 , J. Boydston 1 , D. Karaolis 3 , S. Cendrowski 3 ; 1 Southern Res. Inst., Birmingham, AL, 2 Alpha StatConsult, Damascus, MD, 3 Natl. Biode- fense Analysis and Countermeasures Ctr., Frederick, MD. ------------------------------------------------------------------------ 166 C1 Poster Session Resistance to Staphylococcus and Other Gram-Positive Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-1351a Meca-Independent High-Level, Beta-Lactam Resistance in Staphylococcus aureus Strains Passaged in Ceftobiprole and Ceftaroline

L. Chan, H. Chambers; Univ. of California, San Francisco, CA. C1-1351b